EUVIMEDEUVIMED entdecken
Crossref

Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes

Alberto Iannalfi, Giulia Riva, Sara Lillo, Lucia Ciccone, Giulia Fontana, Silvia Molinelli, Luca Trombetta, Mario Ciocca, Sara Imparato, Mattia Pecorilla, Ester Orlandi

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04751-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Alberto Iannalfi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, 27100, Italy. Hauptthemen laut MEDLINE: Meningioma, Proton Therapy, Meningeal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To report the outcomes of a large series of intracranial meningiomas (IMs) submitted to proton therapy (PT) with curative intent. METHODS: We conducted a retrospective analysis on all consecutive IM patients treated between 2014 and 2021. The median PT prescription dose was 55.8 Gy relative biological effectiveness (RBE) and 66 GyRBE for benign/radiologically diagnosed and atypical/anaplastic IMs, respectively. Local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), overall survival (OS), and radionecrosis-free survival (RNFS) were evaluated with the Kaplan-Meier method. Univariable analysis was performed to identify potential prognostic factors for clinical outcomes. Toxicity was reported according to the latest Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS: Overall, 167 patients were included. With a median follow-up of 41 months (range, 6-99), twelve patients (7%) developed tumor local recurrence after a median time of 39 months. The 5-year LRFS was 88% for the entire cohort, with a significant difference between benign/radiologically diagnosed and atypical/anaplastic IMs (98% vs. 47%, p < 0.001); this significant difference was maintained also for the 5-year OS and the 5-year DRFS rates. Patients aged ≤ 56 years reported significantly better outcomes, whereas lower prescription doses and skull base location were associated with better RNFS rates. Two patients experienced G3 acute toxicities (1.2%), and three patients G3 late toxicities (1.8%). There were no G4-G5 adverse events. CONCLUSION: PT proved to be effective with an acceptable toxicity profile. To the best of our knowledge this is one of the largest series including IM patients submitted to PT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaProton TherapyMeningeal NeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAgedAged, 80 and overYoung AdultFollow-Up StudiesTreatment OutcomeSurvival RateNeoplasm Recurrence, LocalPrognosis

Stichwörter der Autor:innen

AnaplasticAtypicalIntracranial meningiomaMeningiomaProton therapyRadiotherapy

Autor:innen und Institutionen

  • Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, 27100, Italy.
  • Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, 27100, Italy. sara.lillo@cnao.it.
  • Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, 27100, Italy.
  • Medical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, 27100, Italy.
  • Radiology Unit, Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, 27100, Italy.
  • Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, 27100, Italy.

Zitieren

APA

Iannalfi, A., Riva, G., Lillo, S., Ciccone, L., Fontana, G., Molinelli, S., Trombetta, L., Ciocca, M., Imparato, S., Pecorilla, M., & Orlandi, E. (2024). Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04751-x

Vancouver

Iannalfi A, Riva G, Lillo S, Ciccone L, Fontana G, Molinelli S, et al. Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04751-x

BibTeX
@article{Iannalfi2024,
  author = {Iannalfi, Alberto and Riva, Giulia and Lillo, Sara and Ciccone, Lucia and Fontana, Giulia and Molinelli, Silvia and Trombetta, Luca and Ciocca, Mario and Imparato, Sara and Pecorilla, Mattia and Orlandi, Ester},
  title = {Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04751-x}
}
Kostenlos starten →